Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma

BACKGROUND: Multiple myeloma (MM) is an incurable plasma cell malignancy, accounting for approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the introduction of proteasome inhibitors (PIs) such as bortezomib (BTZ) and carfilzomib (CFZ), relapses and disease progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandini, Cecilia, Mereu, Elisabetta, Paradzik, Tina, Labrador, Maria, Maccagno, Monica, Cumerlato, Michela, Oreglia, Federico, Prever, Lorenzo, Manicardi, Veronica, Taiana, Elisa, Ronchetti, Domenica, D’Agostino, Mattia, Gay, Francesca, Larocca, Alessandra, Besse, Lenka, Merlo, Giorgio Roberto, Hirsch, Emilio, Ciarrocchi, Alessia, Inghirami, Giorgio, Neri, Antonino, Piva, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413620/
https://www.ncbi.nlm.nih.gov/pubmed/37563685
http://dx.doi.org/10.1186/s40164-023-00434-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413620/
https://www.ncbi.nlm.nih.gov/pubmed/37563685
http://dx.doi.org/10.1186/s40164-023-00434-x

Ejemplares similares